eMedicine Specialties > Radiology > Brain/Spine
Ganglioneuroma and Ganglioneuroblastoma: Imaging
Updated: Jun 18, 2009
Radiography
This radiograph of a ganglioneuroma shows a right paraspinal well-defined density that appears to be retrocardiac. The right cardiophrenic angle appears normal.
This radiograph of a ganglioneuroblastoma shows a large, well-defined homogeneous density in the left paraspinal region. The lesion is silhouetting the aorta and, on the lateral view appears, to be retrocardiac and in close proximity to the vertebral column.
This radiograph of a ganglioneuroblastoma shows a large, well-defined homogeneous density in the left paraspinal region. The lesion is silhouetting the aorta and, on the lateral view, appears to be retrocardiac and in close proximity to the vertebral column.
Findings
On radiologic examination, all neuroblastic tumors (ie, ganglioneuroblastomas, ganglioneuromas, and neuroblastomas) look similar. The main difference is that ganglioneuroblastomas and neuroblastomas can possibility metastasize.
These tumors have highly variable radiologic appearances and growth behaviors that are reflective of their variable locations. Conventional radiographs show a retroperitoneal, posterior mediastinal, pelvis, or neck mass. Up to 30% of these tumors may show calcifications. Rib and vertebral foraminal erosions, increased intercostal spaces, and vertebral body pedicle erosions may be seen with both retroperitoneal and posterior mediastinal tumors. Hepatomegaly, periostitis, widened cranial sutures, focal bone lucencies, focal bone sclerosis, and lucent submetaphyseal zones may indicate metastatic disease.4
Computed Tomography
T1-weighted CT scan images of a ganglioneuroma. The sagittal views demonstrate a well-defined solid mass located slightly anterior to the mid-thoracic vertebral bodies. The mass is extending into the neural foramina, with widening of the neural foramina. The flow void within the lesion represents vascularity.
This axial noncontrast-enhanced CT image of a ganglioneuroblastoma demonstrates a large left heterogeneous paraspinal lesion with speckled calcifications that are predominantly peripheral.
Findings
CT scanning is the imaging modality that is most commonly used to evaluate neuroblastic tumors. It has proven to be the superior imaging technique when identifying tumor size, organ of origin, tissue invasion, vascular encasement, adenopathy, and calcifications. Newly diagnosed cases are evaluated with standard chest, abdominal, and pelvic CT scans.4
Ganglioneuromas
Retroperitoneal and adrenal ganglioneuromas appear well-defined. Their shape ranges from round to lobulated, they show discrete and punctate calcifications in 42-60% of cases, and they tend to grow around major blood vessels. The tumors do not compress these blood vessels, and blood flow remains normal.1
Nonenhanced CT scanning reveals a homogeneous mass with less attenuation than muscle. Ichikawa et al described a delayed heterogeneous uptake of contrast in a ganglioneuroma.20 The reason for this type of uptake is that these tumors take longer to accumulate contrast material in the extracellular space. This delay is directly proportional to the amount of myxoid stroma in the tumor.
Ganglioneuroblastomas
Ganglioneuroblastomas have a variable appearance on CT and can be cystic or solid.1 Abdominal and pelvic tumors are mostly heterogeneous and large; smaller tumors may appear homogeneous.
Areas of bleeding and necrosis may be as large as 4 cm and appear to be of lower attenuation. These tumors can grow around blood vessels but rarely invade them. Vessel compression, however, is a realistic possibility. If compression of renal vasculature occurs, hypertension can result.4 Other vessels at risk include the splenic vein, inferior vena cava, aorta, celiac artery, and superior mesenteric artery (SMA).
Any metastasis to the liver or lung and adenopathy can also be identified on CT. Liver metastases appear as diffuse infiltration (in infants) and as focal areas of low enhancement.
Metastatic disease of the lung can appear either as well-defined nodules or as larger areas of tissue consolidation. Although exceedingly rare, brain metastases do occur and have a variable appearance, ranging from hemorrhagic to cystic with rim-enhancement to a solid mass.
Intracranial dural involvement is a more common occurrence and can be seen as meningeal masses and meningeal enhancement. These metastatic tumors may be large enough to produce mass effect on the brain and cranium (suture widening). Metastatic involvement of the sphenoid bone that extends into the orbits produces a red and blue discoloration of the orbits that can be misinterpreted as physical abuse.21
Magnetic Resonance Imaging
This coronal T2-weighted image demonstrates a well-defined, lobulated mass with fibrous septations. The mass is extending into the neural foramina and is causing cord compression in the midthoracic region. The mass is also displacing the aorta to the right.
This coronal T2-weighted image demonstrates a well-defined, lobulated mass with fibrous septations. The mass is extending into the neural foramina and is causing cord compression in the midthoracic region. The mass is also displacing the aorta to the right.
This coronal T2-weighted image demonstrates a well-defined, lobulated mass with fibrous septations. The mass is extending into the neural foramina.
Findings
MRI is a multiplanar imaging technique that creates images with better tissue discrimination than CT. This makes MRI more effective at evaluating organs of origin, regional invasion, and intraspinal tumoral extension. Any patient with a paraspinal tumor should undergo an MRI to evaluate possible tumoral invasion of the epidural space. In these cases, coronal, sagittal, and axial views can demonstrate spinal cord and nerve root displacement as well as superior and inferior tumor growth.
MRI is also useful for imaging bone marrow; the lesions appear hypointense on T1-weighted images and hyperintense on T2-weighted images.
Lastly, MRI can be used to detect hepatic metastases in infants with stage 4S disease, which can be missed on CT scanning because of its appearance as a uniform increase in liver attenuation. These lesions appear hyperintense on T2-weighted MRIs.4,22
Ganglioneuromas
Ganglioneuromas appear homogeneous on MRIs and have a relatively intermediate signal intensity on all sequences.23 Tumors with intermediate-to-high signal-intensity on T2-weighted images have a higher degree of cellularity and more collagen. These tumors will have a small myxoid component. Markedly-high T2 intensity, on the other hand, signifies a high myxoid stroma component and low cellularity and collagen amounts.1
Ganglioneuromas have characteristic curvilinear bands of low signal-intensity on T2-weighted images that impart a whorled pattern to the tumor. These bands are composed of collagen fibers and intertwined bundles of Schwann cells. The capsule surrounding the tumor appears as a low-density ring on both T1- and T2-weighted images.
Contrast enhancement with MRI is similar to contract enhancement with CT imaging. Early contrast enhancement occurs in areas of relatively high vascularity with high capillary permeability. Delayed enhancement, on the other hand, results when diffusion of the enhancing material into the extravascular space is slowed or impeded.24 Therefore, fibrous tissues show slow or late enhancement. These tumors enhance gradually, with final enhancement ranging from none to marked. MRI is the modality of choice for evaluating the extension of spinal tumors.4
Ganglioneuroblastomas
Ganglioneuroblastomas appear heterogeneous on MRIs, with variable enhancement and low signal-intensity on T1-weighted images and high signal-intensity on T2-weighted images.10 Tumor calcifications are more difficult to appreciate on MRIs than on CT scans; on MRIs, they appear as signal voids. Areas of hemorrhage have a high T1 signal-intensity and cystic areas have a high T2 signal-intensity.4 Ganglioneuroblastomas, like neuroblastomas and other malignant tumors, have an enhancing pattern of early enhancement followed by a partial washout; early enhancement is indicative of high vascularity.24
False Positives/Negatives
The differential diagnosis of ganglioneuroma and ganglioneuroblastoma includes neuroblastoma, adrenal adenoma, adrenal carcinoma, neurofibroma, schwannoma, and pheochromocytoma. Ganglioneuromas can be differentiated from more aggressive neuroblastomas and ganglioneuroblastomas by their regular contours and lack of tissue invasion and vessel encasing, their occurrence in older patients, and their discrete, punctate calcifications on CT scans. Neuroblastomas and ganglioneuroblastomas tend to have amorphous or coarse calcifications. In addition, ganglioneuromas rarely metastasize, whereas neuroblastomas and ganglioneuroblastomas can metastasize to bone, skin, and other organs.24
It is more difficult to differentiate ganglioneuromas from schwannomas or neurofibromas. In general, schwannomas and neurofibromas are round and can cause bone erosion and destruction. Most ganglioneuromas are flat and elongated and they normally do not affect bone. Schwannomas may demonstrate cystic degeneration that does not occur in ganglioneuromas. Neurofibromas do not have a capsule; the presence of one in a patient would point to a ganglioneuroma diagnosis.24
Adrenal disease can be differentiated from neuroblastic tumors by its unique enhancing patterns. Adrenal adenomas enhance and wash out early, whereas pheochromocytomas and adrenocortical carcinomas strongly enhance early but wash out at a slower rate. Adrenal carcinomas invade vascular structures in more than 50% of the cases.24
Ultrasonography
Findings
Ganglioneuromas
Ultrasonography of a ganglioneuroma would show a homogeneous, hypoechoic, well-circumscribed mass.22
Ganglioneuroblastomas
Ganglioneuroblastomas show heterogeneic echogenicity, with areas of hemorrhage and necrosis appearing anechogeneic. Calcifications appear as either focal or diffuse areas of increased echogenicity with variable appearance of shadowing. Ultrasonography has proven to be useful in evaluating other organs for metastasis, and for determining blood flow in blood vessels surrounded by tumor.4
Nuclear Imaging
Findings
In cases of ganglioneuroblastoma, scintigraphy is not only useful for identifying the primary tumor, but it is also useful for monitoring the pattern of metastatic spread. Primary and metastatic tumors take up catecholamine and somatostatin analogs.
Iodine-tagged metaiodobenzylguanidine (MIBG), a catecholamine analog, is used to identify catecholamine-producing tumors such as ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, carcinoid tumor, and medullary thyroid cancer.25,26,27,28
Technetium-99m testing is an initial study done in all patients with diagnosed ganglioneuroblastoma. This test is conducted to determine the amount of metastatic disease present; however, as many as 75% of primary tumors also show uptake. This method is preferred for the examination of bone metastases as cortical and marrow lesions are difficult to discriminate (as they are with MIBG studies). Metastases appear as areas of higher uptake, and they include areas such as the lung and liver. The amount of technetium-99m uptake is, purportedly, directly related to calcium metabolism of the tumor cells.
Ganglioneuromas can accumulate MIBG in a fashion similar to ganglioneuroblastomas; tumors that uptake MIBG are catecholamine-producing tumors.25,26,27,28
Degree of Confidence
Although 90-95% of ganglioneuroblastomas produce catecholamines, only approximately 70% take up MIBG. Therefore, negative results do not mean there is no disease. Despite this limitation, MIBG scintigraphy has an 88% sensitivity and a 99% specificity for tumors containing sympathetic tissue, such as ganglioneuroblastomas, ganglioneuromas, neuroblastomas, pheochromocytomas, and carcinoids. The disadvantage is that there is no way to discriminate the type of tumor in which the uptake occurs. When bone is affected, this method also makes staging difficult, because it does not distinguish cortical involvement from marrow involvement.
Unfortunately, up to 50% of recurrent tumors do not take up MIBG. This makes MIBG scintigraphy a poor method of post-therapeutic monitoring for recurrences. Somatostatin-analog testing is also used to evaluate neuroblastic tumors, but it is not as specific as an MIBG study.4
More on Ganglioneuroma and Ganglioneuroblastoma |
| Overview: Ganglioneuroma and Ganglioneuroblastoma |
Imaging: Ganglioneuroma and Ganglioneuroblastoma |
| Follow-up: Ganglioneuroma and Ganglioneuroblastoma |
| Multimedia: Ganglioneuroma and Ganglioneuroblastoma |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
Rha SE, Byun JY, Jung SE, et al. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics. Jan-Feb 2003;23(1):29-43.
De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. Apr 1 2008;26(10):1710-6. [Medline].
Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors:recommendations by the International Neuroblastoma Pathology Committee. Cancer. Jul 15 1999;86(2):349-63. [Medline].
Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. Jul-Aug 2002;22(4):911-34. [Medline].
Shin JH, Lee HK, Khang SK, et al. Neuronal tumors of the central nervous system: radiologic findings and pathologic correlation. Radiographics. Sep-Oct 2002;22(5):1177-89. [Medline].
Maweja S, Materne R, Detrembleur N, de Leval L, Defechereux T, Meurisse M. Adrenal ganglioneuroma. Am J Surg. Nov 2007;194(5):683-4. [Medline].
Geoerger B, Hero B, Harms D, et al. Metabolic activity and clinical features of primary ganglioneuromas. Cancer. May 15 2001;91(10):1905-13. [Medline].
Brouwers FM, Eisenhofer G, Lenders JW, Pacak K. Emergencies caused by pheochromocytoma, neuroblastoma, or ganglioneuroma. Endocrinol Metab Clin North Am. Dec 2006;35(4):699-724, viii. [Medline].
Patterson AR, Barker CS, Loukota RA, Spencer J. Ganglioneuroma of the mandible resulting from metastasis of neuroblastoma. Int J Oral Maxillofac Surg. Nov 17 2008;[Medline].
Gasparetto EL, Rosemberg S, Matushita H, da Costa Leite C. Ganglioneuroblastoma of the cerebellum: neuroimaging and pathological features of a case. Arq Neuropsiquiatr. Jun 2007;65(2A):338-40. [Medline].
Dozois EJ, Wall JC, Spinner RJ, Jacofsky DJ, Yaszemski MJ, Sim FH, et al. Neurogenic tumors of the pelvis: clinicopathologic features and surgical outcomes using a multidisciplinary team. Ann Surg Oncol. Apr 2009;16(4):1010-6. [Medline].
Coldman AJ, Fryer CJ, Elwood JM, Sonley MJ. Neuroblastoma: influence of age at diagnosis, stage, tumor site, and sex on prognosis. Cancer. Oct 15 1980;46(8):1896-1901. [Medline].
Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood. Feb 1 2007;109(3):926-35. [Medline].
Joshi VV. Peripheral neuroblastic tumors: pathologic classification based on recommendations of international neuroblastoma pathology committee (Modification of shimada classification). Pediatr Dev Pathol. Mar-Apr 2000;3(2):184-99. [Medline].
Catalina-Fernández I, Sáenz-Santamaria J, López-Presa D. Fine needle aspiration cytology of ganglioneuroma. Acta Cytol. May-Jun 2008;52(3):380-1. [Medline].
Brossard J, Bernstein ML, Lemieux B. Neuroblastoma: an enigmatic disease. British Medical Bulletin. 1996;52:787-801.
Rabah R, Weber R, Serhatkulu GK, Cao A, Dai H, Pandya A. Diagnosis of neuroblastoma and ganglioneuroma using Raman spectroscopy. J Pediatr Surg. Jan 2008;43(1):171-6. [Medline].
Guo YK, Yang ZG, Li Y, Deng YP, Ma ES, Min PQ, et al. Uncommon adrenal masses: CT and MRI features with histopathologic correlation. Eur J Radiol. Jun 2007;62(3):359-70. [Medline].
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, et al. Detecting Minimal Residual Disease in Neuroblastoma: the Superiority of a Panel of Real-Time Quantitative PCR Markers. Clin Chem. May 21 2009;[Medline].
Ichikawa T, Ohtomo K, Araki T, et al. Ganglioneuroma: computed tomography and magnetic resonance features. Br J Radiol. Feb 1996;69(818):114-21. [Medline].
Abramson SJ. Adrenal neoplasms in children. Radiol Clin North Am. Nov 1997;35(6):1415-53. [Medline].
Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F. Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary?. Eur J Radiol. Apr 13 2009;[Medline].
Tanaka O, Kiryu T, Hirose Y, Iwata H, Hoshi H. Neurogenic tumors of the mediastinum and chest wall: MR imaging appearance. J Thorac Imaging. Nov 2005;20(4):316-20. [Medline].
Zhang Y, Nishimura H, Kato S, et al. MRI of ganglioneuroma: histologic correlation study. J Comput Assist Tomogr. Jul-Aug 2001;25(4):617-23. [Medline].
Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. May 5 2009;100(9):1471-82. [Medline].
Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. Dec 2008;52(4):388-402. [Medline].
Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. Jul 2009;52(7):784-90. [Medline].
Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. Dec 2008;52(4):403-18. [Medline].
Lacreuse I, Valla JS, de Lagausie P, Varlet F, Héloury Y, Temporal G, et al. Thoracoscopic resection of neurogenic tumors in children. J Pediatr Surg. Oct 2007;42(10):1725-8. [Medline].
de Torres C, Beleta H, Díaz R, Toran N, Rodríguez E, Lavarino C, et al. The calcium-sensing receptor and parathyroid hormone-related protein are expressed in differentiated, favorable neuroblastic tumors. Cancer. Jun 15 2009;115(12):2792-803. [Medline].
Izbicki T, Mazur J, Izbicka E. Epidemiology of neuroblastoma: analysis of a single institution. Anticancer Res. Mar-Apr 2003;23(2C):1933-8. [Medline].
Okamatsu C, London WB, Naranjo A, Hogarty MD, Gastier-Foster JM, Look AT, et al. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatr Blood Cancer. Jun 15 2009;[Medline].
Piqueras M, Navarro S, Castel V, Cañete A, Llombart-Bosch A, Noguera R. Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors. Pediatr Blood Cancer. Feb 2009;52(2):209-14. [Medline].
Shimada H, Umehara S, Monobe Y, Hachitanda Y, Nakagawa A, Goto S. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group. Cancer. Nov 1 2001;92(9):2451-61. [Medline].
Vermeulen J, De Preter K, Naranjo A, Vercruysse L, Van Roy N, Hellemans J, et al. Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. Jun 8 2009;[Medline].
Further Reading
Related eMedicine topics
Neurogenic Tumors of the Mediastinum
Neuroblastoma (Radiology)
Neuroblastoma (Pediatrics: General Medicine)
Neuroblastoma (Urology)
Ganglioglioma
Clinical studies
Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma
Gene Therapy in Treating Children With Relapsed or Refractory Neuroblastoma
Clinical trials
A Phase I/Ii Study Of Immunization With Lymphotactin And Interleukin 2 Gene Modified Neuroblastoma Tumor Cells After High-Dose Chemotherapy And Autologous Stem Cell Rescue In Patients With High Risk Neuroblastoma
Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma
Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma
Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Keywords
ganglioneuroma, ganglioneuroblastoma, GN, GNB, neurogenic tumors, neuroblastoma, neuroblastic tumors, schwannoma, malignant schwannoma, pheochromocytoma, neuroblastoma, neurogenic cyst, neurilemoma, neurofibroma, neurogenic neoplasm, von Recklinghausen disease, neurofibromatosis, paraganglionoma, peripheral neuroectodermal tumors, PNET, sympathetic nervous system tumors, SNS tumors, pepper syndrome, blueberry muffin syndrome
















Imaging: Ganglioneuroma and Ganglioneuroblastoma